CJC-1295 (No DAC) vs MK-677
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CJC-1295 DAC, CJC-1295 no DAC
A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
Also: Ibutamoren, Nutrobal
An orally active growth hormone secretagogue that mimics ghrelin. Although technically not a peptide, it is frequently discussed alongside GH peptides due to similar effects.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
Detailed Comparison
| Attribute | CJC-1295 (No DAC) | MK-677 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | CJC-1295 binds to GHRH receptors on the pituitary, stimulating GH synthesis and release. The DAC (Drug Affinity Complex) version binds to albumin, extending half-life to 6-8 days. Without DAC (Mod GRF 1-29), half-life is about 30 minutes. | MK-677 binds to ghrelin receptors (GHSR) in the brain, stimulating sustained GH release and increasing IGF-1 levels. Unlike injectable GHRPs, it is orally bioavailable and has a long half-life providing 24-hour GH elevation. |
| Common Dosing | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) Daily (no DAC) or 1-2x weekly (with DAC) | 10-25 mg daily Once daily, often before bed |
| Administration | Subcutaneous injection | Oral |
| Typical Duration | 8-12 weeks | 8-12 weeks or longer |
| Best Time to Take | Before bed | Before bed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase II trial in HIV lipodystrophy patients was discontinued after a patient death (MI, deemed unrelated but trial ended as precaution). Earlier studies show sustained 2-10 fold increase in GH and IGF-1 levels with good tolerability at doses up to 60 mcg/kg. | Studies show increases in GH and IGF-1 levels, improved sleep quality, and increased lean body mass. However, a clinical trial was stopped early due to heart failure concerns in elderly patients. FDA lists MK-677 as having 'significant safety risks due to potential for congestive heart failure.' December 2025: FDA issued warning letters to companies selling MK-677. Never received FDA approval and remains an unapproved drug. |
Frequently Asked Questions: CJC-1295 (No DAC) vs MK-677
What is the difference between CJC-1295 (No DAC) and MK-677?
CJC-1295 (No DAC) is a growth hormone peptide that a synthetic analog of growth hormone-releasing hormone (ghrh) that stimulates gh release from the pituitary. often combined with a ghrp like ipamorelin for synergistic effects. MK-677 is a growth hormone peptide that an orally active growth hormone secretagogue that mimics ghrelin. although technically not a peptide, it is frequently discussed alongside gh peptides due to similar effects. The main differences lie in their mechanisms of action and clinical applications.
Which is better, CJC-1295 (No DAC) or MK-677?
Neither is universally "better" - the choice depends on your specific goals. CJC-1295 (No DAC) is typically used for growth hormone purposes, while MK-677 is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can CJC-1295 (No DAC) and MK-677 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using CJC-1295 (No DAC) and MK-677 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.